Foley Hoag LLP represented Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company, in its underwritten public offering of 6,500,000 shares of common stock at a public offering price of $5.00 per share, less underwriting discounts and commissions.
With headquarters in Alachua, FL and an office facility in Cambridge, MA, AGTC uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, in which it has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, otology and adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which are diseases of the central nervous system (CNS), and other ophthalmology indications.
The Foley Hoag team consisted of Stacie Aarestad, Ryan Rourke Reed, Caroline Samp, Mark Jorgensen, and specialist help was provided by John Hancock and Malcolm Henderson.